About Momenta Sample Clauses

About Momenta. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. To receive additional information about Momenta, please visit the website at xxx.xxxxxxxxxxxxx.xxx, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners. Forward Looking Statement For Momenta Pharmaceuticals Statements in this press release regarding management’s future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements concerning the collaboration agreement between Mylan N.V. and Momenta Pharmaceuticals, Inc., including anticipated payments, as well as future development, manufacture, and commercialization of biosimilars under the agreement; and our and Mylan’s ability to successfully develop and commercialize high quality, cost-effective biosimilar products, compete successfully in biosimilars, and increase shareholder value. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “hope,” “target,” “project,” “goal,” “objective,” “guidance,” “plan,” “potential,” “predict,” “might,” “estimate,” “expect,” “intend,” “may,” “seek”, “should,” “will,” “would,” “look forward” and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including receiving clearance under the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act and those referred to under the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, or the risks and factors noted below by Mylan N.V., ...
Sample 1
AutoNDA by SimpleDocs
About Momenta. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 and is headquartered in Cambridge, Mass. This release includes forward-looking statements concerning a collaboration agreement between Xxxxxx International Inc. and Momenta Pharmaceuticals, Inc., including expectations with respect to the closing of the transaction and milestone payments. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of closing conditions, including expiration of the waiting period under the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety issues; and other risks identified in each of the company’s most recent filings on Form 10-K and other SEC filings. Neither Baxter nor Momenta undertakes to update its forward-looking statements. ###
Sample 1
About Momenta. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA. To receive additional information about Momenta, please visit the website at xxx.xxxxxxxxxxxxx.xxx, which does not form a part of this press release. Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners. CONTACT: Xxxxxxx Xxxxxx Director, Investor Relations xxxxxxx@xxxxxxxxxxxxx.xxx 000-000-0000 Source: Momenta Pharmaceuticals News Provided by Acquire Media EXHIBIT H FORM OF CONSENT OF [**] VIRDANTE PHARMACEUTICALS, INC. 000 Xxxx Xxxxxx, Xxxxx 0000 Xxxxxxxxx, XX 00000 November 21, 2011 Via E-mail and Federal Express [**]
Sample 1

Related to About Momenta

  • SERVICE MONITORING, ANALYSES AND ORACLE SOFTWARE 11.1 We continuously monitor the Services to facilitate Oracle’s operation of the Services; to help resolve Your service requests; to detect and address threats to the functionality, security, integrity, and availability of the Services as well as any content, data, or applications in the Services; and to detect and address illegal acts or violations of the Acceptable Use Policy. Oracle monitoring tools do not collect or store any of Your Content residing in the Services, except as needed for such purposes. Oracle does not monitor, and does not address issues with, non-Oracle software provided by You or any of Your Users that is stored in, or run on or through, the Services. Information collected by Oracle monitoring tools (excluding Your Content) may also be used to assist in managing Oracle’s product and service portfolio, to help Oracle address deficiencies in its product and service offerings, and for license management purposes.

  • Management of Special and Technical Environment Each certificated support person demonstrates an acceptable level of performance in managing and organizing the special materials, equipment and environment essential to the specialized programs.

  • INTERNET PLANNING, ENGINEERING AND OPERATIONS ‌ Job Title: Internet/Web Engineer Job#: 2620 General Characteristics Integrally involved in the development and support of all Internet/Intranet/Extranet sites and supporting systems. Works closely with other IT groups and customers to define the system design and user interface based on customer needs and objectives. Participates in all phases of the development and implementation process, and may act as a project manager on special projects. Ensures the integration of the Web servers and all other supporting systems. Responsible for system tuning, optimization of information/data processing, maintenance and support of the production environment.

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

  • How Do I Get More Information? This Settlement Notice does not fully describe all of the claims, defenses, or contentions of the parties. If you have questions about this Notice or the Action, please do not contact the Court. If you have questions regarding the Settlement, you can call Class Counsel at 0-000-000-0000, email Class Counsel at xxxxxxx@xxxxxxxxxxxxxxxxx.xxx, call the Settlement Administrator at 0-000-000-0000, write to the Settlement Administrator at JPM Stable Value Fund Litigation c/o JND Class Action Administration, P.O. Box 91304, Seattle, WA 98111, or go to the following website: xxx.xxxxxxxxxxxxxxxxx.xxx where you will find the Court’s order certifying the Class, the Plaintiffs’ Consolidated and Amended Complaint, the Defendants’ Answer to the Consolidated and Amended Complaint, the Settlement Agreement, and information regarding the day, time, and location of the Fairness Hearing once it has been scheduled by the Court. Other filings with the Court and information regarding the Settlement are also available online. Dated: , 2017 BY THE ORDER OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK ATTACHMENT 1 PLAN SPONSOR 1 1888 XXXXX, LLC 2 X.X. XXXXXXXX CO., INC. 3 ABILENE CHAMBER OF COMMERCE 4 ABITIBI CONSOLIDATED SALES CORPORATION 5 ACCE BENEFIT TRUST 6 ACCE BENEFITS TRUST 7 ACCE BENEFITS TRUST 401(K) PLAN 8 ADVANCED MEDICAL OPTICS, INC. 9 AGGREKO, LLC 10 AJAX PAVING INDUSTRIES OF FLORIDA, INC. 11 AJAX PAVING INDUSTRIES, INC. 12 ALASKA TANKER COMPANY ATC 13 ALCON LABS 14 ALLERGAN INC 15 ALM MEDIA INC. 16 ANCHOR ACQUISITION, LLC 17 AMARILLO CHAMBER OF COMMERCE 18 AMERICAN CHAMBER OF COMMERCE EXECUTIVES 19 AMERICAN CIVIL CONSTRUCTORS, INC. 20 AMERICAN LIGHTING ASSOCIATION 21 AMERICAN ROYAL ASSOCIATION 22 AMERICAN TECHNOLOGIES, INC. 23 ALLIANT ENERGY CORPORATE SERVICES, INC. 24 AMERICAN ELECTRIC POWER SERVICE CORP. (AEP) 25 XXXXXXXX CORP. 26 XXXXXX CORP. 27 ANGELO'S AGGREGATE MATERIALS, LTD. 28 XXXX TRUCKING L.L.C. 29 APAC PAPER & PACKAGING CORP. 30 ARBOR MANAGEMENT, INC. 31 ARCH CHEMICAL INC. 32 AREA ENERGY & ELECTRIC, INC. 33 ARGO GROUP US 34 ARIZONA CHEMICAL COMPANY PLAN SPONSOR 35 ARLINGTON METALS CORPORATION 36 ASPHALT PAVING, INC. 37 ASSOCIATED WHOLESALE GROCERS, INC. 38 ASTEC INDUSTRIES, INC. 39 ASTELLAS US LLC 40 ATLANTIC SOUTHEAST AIRLINES, INC 41 AUDIO AUTHORITY CORPORATION 42 AUGUSTA NEWSPRINT COMPANY 43 AVON PRODUCTS, INC. 44 X.X. XXXXXXXX / XXXXXXXX / UNITED TECHNOLOGIES CORPORATION (UTC) 45 BADGERLAND SUPPLY. INC. 46 BAESMAN PRINTING CORPORATION 47 BANK OF COMMERCE & TRUST COMPANY 48 BATON ROUGE AREA CHAMBER PROFIT SHARING PLAN 49 XXXXXXX XXXXXX COMPANY LLC 50 XXXX TOYOTA CORP. 51 BEECHMONT PRESS, LLC 52 XXXX INC. 53 BELL CORP. 54 XXXXX COMPANY, INC. 55 BENESYS, INC. 56 XXXXXXX, XXXXXXX, XXXXXXX AND DAVIS APLC 57 BEST BUY 58 BIGSTON CORPORATION 59 BIOMEDICAL RESEARCH FOUNDATION 60 BISON GEAR ENG. CORP 61 BOC XXXXXXX, INC. 62 BOISE CONVENTION & VISITORS BUREAU PROFIT 63 BOISE METRO CHAMBER OF COMMERCE 64 BOSE CORP. 65 XXXXXX AND XXXXXX P.A. 66 XXXXXX & XXXXXXXX CORPORATION 67 XXXXX XXXXX COMPANY 68 BROOK FURNITURE RENTAL INC. 69 XXXXXXXXXX HOLDINGS, INC. 70 BROWN AND XXXXXXXX PLAN SPONSOR 71 BUCKEYE PIPE LINE SERVICES COMPANY 72 XXXX-O-MATIC CORPORATION 73 X.X. ENTERPRISES 74 CANBERRA OAK RIDGE, LLC 75 CARATRON INDUSTRIES, INC. 76 XXXXXXX INC. 77 CARL ZEISS VISION INC. 78 XXXX INDUSTRIES, INC. 79 XXXXXX MACHINERY CO. 80 CATERPILLAR INC. 81 CDM FEDERAL SERVICES, INC. 82 CELANESE (HOECHST CELANESE) 83 CENTRALIZED LABORATORY SERVICES INC 84 CERNER CORP. 85 CHATTANOOGA AREA CHAMBER OF COMMERCE 86 CHRISTIAN REFORMED CHURCH IN NORTH AMERICA 87 CINCINNATI TOOL STEEL COMPANY 88 XX XXXXXX CONSTRUCTION COMPANY 89 CLARIAN HEALTH / INDIANA UNIV. HEALTH INC. 90 XXXXXX QUALITY COATINGS, INC. 91 CLEAR LAKE AREA CHAMBER OF COMMERCE 92 XXXX HARDWOOD INC. 93 XXXXXXX & XXXXXX PRODUCTS CO. 94 COLONIAL PIPELINE CO. 95 COMMODORE ADVANCE SCIENCES, INC. 96 COMSYS IT PARTNERS INC. 97 CONNING & COMPANY 98 COOK COMPOSITES & POLYMERS COMPANY 99 COOPERATIVE REGIONS OF ORGANIC PRODUCER POOLS COOPERATIVE, INC. 100 CROWN EQUIPMENT CORP. 101 CSK AUTO, INC. 102 CUMMINS INC. 103 XXXXXXX & XXXXXXXXX, INC. 104 DACO INCORPORATED 105 DAKOTA CLINIC / INNOVIS HEALTH 106 DALLAS REGIONAL CHAMBER PLAN SPONSOR 107 DASCO PRO INC. 108 DETROIT LEGAL NEWS COMPANY 109 XXXX XXXXXX INC. 110 DIRECT GENERAL CORPORATION 111 XXX X. XXXXXXX, INC. 112 XXXXXXX COMPANIES INC. 113 DOTT INDUSTRIES, INC. 114 DOWCO INC. 115 DURATEK FEDERAL SERVICES, INC. 116 X.X. XXXXXXX COMPANY 117 EAGLE-PICHER CORPORATION 118 XXXX XXXXX CO. INC. 119 EDISON ELECTRIC INSTITUTE INC. 120 EET CORPORATION 121 XXX XXXXX 122 ELKAY MANUFACTURING COMPANY 123 ELMER'S PRODUCTS INC. 124 EMPIRE LEVEL MANUFACTURING CORP. 125 ENERCON ENGINEERING, INC. 126 ENERGY EAST CORP. 127 ENERGY NORTHWEST 128 XX XXXX GROUP, L.P. 129 ERICSSON INC. 130 XXXXX XXXXX GLOBAL INC. 131 E-S PLASTIC PRODUCTS INC. 132 FATHER XXXXXXXX'X BOYS' HOME 133 XXXXXXX COMPANIES, INC. 134 FERRO CORP. 135 XXXXXX & COMPANY, INCORPORATED 136 FITCH, INC. 137 FIVE STAR DISTRIBUTING, INC. 138 XXXXXXXXX & XXXX 139 FOREMOST FARMS USA 140 FOREST LABORATORIES, INC. 141 FLORIDA CHAMBER OF COMMERCE 142 FLORIDA GAS TRANSMISSION COMPANY 143 FLO-TORK, INC. PLAN SPONSOR 144 FOX CITIES CHAMBER OF COMMERCE & INDUSTRY 145 XXXXX X. XXXX COMPANY 146 FREEPORT MCMORAN / XXXXXX DODGE CORP. 147 XXXXXXX DENVER, INC. 148 GERLIN, INC. DBA CORE PIPE PRODUCTS, INC. 149 GENERAC 150 GENERAL XXXXX 151 XXX CONSULTANTS, LLC 152 GHP OPERATING COMPANY LLC (GLOBAL HOME PRODUCTS) 153 XXXXXXXX / PROCTER & XXXXXX 154 GLENMARK INDUSTRIES INC. 155 GPD, INC. 156 GREAT PLAINS ENERGY INCORPORATED 157 GREATER BINGHAMTON CHAMBER OF COMMERCE 000 XXXXXXX XXXXXXXXXX XXXXXXX OF COMMERCE 159 GREATER XXXXXXX CHAMBER PARTNERSHIP 160 GREATER LOUISVILLE INC. 161 GREATER NEW HAVEN CHAMBER OF COMMERCE 162 GREATER PROVIDENCE CHAMBER OF COMMERCE 163 GREATER RALEIGH CHAMBER OF COMMERCE 164 GREATER READING CHAMBER OF COMMERCE/INDUSTRY 165 GREATER SCRANTON CHAMBER OF COMMERCE 166 GREATER TAMPA CHAMBER OF COMMERCE 167 GREATER TOPEKA CHAMBER OF COMMERCE 168 GREATER WACO CHAMBER OF COMMERCE 169 GREATER WASHINGTON BOARD OF TRADE 170 GREEN DIAMOND RESOURCE COMPANY 171 GREEN THUMB LAWNSCAPING, INC. 172 GRINDMASTER CORPORATION 173 XXXXXXXXX LUMBER & SPPLY, INC. 174 GZA GEOENVIRONMENTAL, INC. 175 H&S TOOLS INC. 176 XXXXX & XXXXXXX INC 177 HAPAQ-XXXXX 178 XXXXXXX ROADS CHAMBER OF COMMERCE 179 XXXXXX PUBLICATIONS, INC.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Appropriate Technical and Organizational Measures SAP has implemented and will apply the technical and organizational measures set forth in Appendix 2. Customer has reviewed such measures and agrees that as to the Cloud Service selected by Customer in the Order Form the measures are appropriate taking into account the state of the art, the costs of implementation, nature, scope, context and purposes of the processing of Personal Data.

  • Condominiums/Planned Unit Developments If the Mortgaged Property is a condominium unit or a planned unit development (other than a de minimis planned unit development) such condominium or planned unit development project such Mortgage Loan was originated in accordance with, and the Mortgaged Property meets the guidelines set forth in the Originator's Underwriting Guidelines;

  • Telemedicine Services This plan covers clinically appropriate telemedicine services when the service is provided via remote access through an on-line service or other interactive audio and video telecommunications system in accordance with R.I. General Law § 27-81-1. Clinically appropriate telemedicine services may be obtained from a network provider, and from our designated telemedicine service provider. When you seek telemedicine services from our designated telemedicine service provider, the amount you pay is listed in the Summary of Medical Benefits. When you receive a covered healthcare service from a network provider via remote access, the amount you pay depends on the covered healthcare service you receive, as indicated in the Summary of Medical Benefits. For information about telemedicine services, our designated telemedicine service provider, and how to access telemedicine services, please visit our website or contact our Customer Service Department.

  • Technical Cooperation 1. The Parties shall strengthen their cooperation in the field of standards, technical regulations, metrology, market surveillance, accreditation and conformity assessment systems with a view to increasing the mutual understanding of their respective systems and facilitating access to their respective markets. To that end, they may establish regulatory dialogues at both horizontal and sectoral levels.

Time is Money Join Law Insider Premium to draft better contracts faster.